Merck And Korea's Hanmi Build On Cozaar Deal From One Country To More Than 30, And More Could Be On The Way
This article was originally published in PharmAsia News
Executive Summary
SEOUL - Merck & Co. Inc.'s emphasis on lifecycle management for its Cozaar brand is good news for Hanmi Pharmaceutical, as Merck recently expanded a marketing rights deal for Hanmi's ARB/CCB combination that pairs amlodipine with Merck's losartan. A deal that started in 2009 for the Korean market now stands at 30 markets and signs point to an even broader deal in the future